Evidence map›Paper›PMID 20576821›Full record

ArticleClinical journal of the American Society of Nephrology : CJASN2010

Long-term treatment with potassium citrate and renal stones in medullary sponge kidney.

Antonia Fabris, Antonio Lupo, Patrizia Bernich, Cataldo Abaterusso, Nicola Marchionna, Antonio Nouvenne, Giovanni Gambaro

Registry-linked trialAbstract read
In one paragraph

Article in Clinical journal of the American Society of Nephrology : CJASN, 2010. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT03007160 (A Randomized, Blank Controlled, Multicenter Clinical Trial of the Effection of Potassium Citrate Extended-release Tablets on Urolithiasis Formation or Recurrence), which is not on this map. Cited by 31 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
31citing papers in PubMed, 1 pooled it
4.1field-weighted citation impact, top 6% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT03007160 phase4unknown statusnot on this mapstarted 2016, after this paper: background citation

A Randomized, Blank Controlled, Multicenter Clinical Trial of the Effection of Potassium Citrate Extended-release Tablets on Urolithiasis Formation or Recurrence

TypeinterventionalSponsorDawnrays Pharmaceutical (Holdings) LimitedRan2016 to 2020Enrolled2,001ConditionsUrolithiasisArmsPotassium Citrate Extended-release Tablets
3 · Its place in the literature

Who cites it

31 citing papers in PubMed, 1 synthesis or guideline pooled it, 84 citations in OpenAlex.

  1. Guideline
  2. Trial
  3. Trial
  4. Urolithiasis in patients with cancer.Nature reviews. Urology · 2026
    Review
  5. Review
  6. Article
  7. Review
  8. Article
  9. Article
  10. Review
  11. Article
  12. Article
  13. Review
  14. Article
  15. Article
  16. ChlorthalidoneAnnals of translational medicine · 2019
    Article
  17. Review
  18. Article
  19. Medullary Sponge Kidney: Current Perspectives.International journal of nephrology and renovascular disease · 2019
    Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 3 institutions in 1 country.

Antonia FabrisDivision of Nephrology, Department of Biomedical and Surgical Sciences, University Hospital of Verona, Verona, Italy.
Antonio Lupo
Patrizia Bernich
Cataldo Abaterusso
Nicola Marchionna
Antonio Nouvenne
Giovanni Gambaro
University of Verona · ITAgostino Gemelli University Polyclinic · ITUniversity of Parma · IT

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

BACKGROUND AND

objectivesMedullary sponge kidney (MSK) is a renal malformation typically associated with nephrocalcinosis and recurrent calcium stones. Incomplete distal renal tubular acidosis, hypocitraturia, and hypercalciuria are common. For stone prevention, patients with MSK generally receive the standard "stone clinic" recommendations and often receive potassium citrate (KC). However, the effect on stone recurrence of citrate treatment in these patients has never been studied. DESIGN, SETTING, PARTICIPANTS, & MEASUREMENTS: The issue was retrospectively analyzed on an outpatient basis in 97 patients with a radiologic diagnosis of MSK: 65 had at least one stone risk factor (SRF; hypercalciuria, hypocitraturia, hyperuricosuria, hyperoxaluria) and received KC [29 +/- 8 (SD) mEq/d]; 10 patients with SRF and 22 without received only general stone clinic suggestions. Follow-up was 78 +/- 13, 72 +/- 15, and 83 +/- 14 months, respectively. The 24-hour urinary excretion of calcium, oxalate, uric acid, citrate, and morning urine pH were investigated at baseline and at the end of follow-up.

resultsParallel to a significant rise in urinary citrate and decreased urinary calcium (all P < 0.001), KC led to a dramatic reduction in the stone event rate (from 0.58 to 0.10 stones/yr per patient). The existence of a group of patients with MSK, those without SRF, with a very low stone rate and no SRF was recognized.

conclusionsTreatment with KC is effective in preventing renal stones in the typical patient with MSK. It seems that two clinical phenotypes among patients showing typical MSK features during radiologic study exist.

Indexed as

AdolescentAdultBiomarkersChi-Square DistributionDrug Administration ScheduleFemaleHumansHydrogen-Ion ConcentrationItalyKidney CalculiMaleMedullary Sponge KidneyPotassium CitrateRadiographyRecurrenceRetrospective StudiesBiomarkersPotassium Citrate

Identifiers

PMID20576821
PMCPMC2974409
OpenAlexW2147782072

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.